Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world?
HBV
elimination
mother-to-child transmission
prevention
vaccine
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
06
08
2019
accepted:
12
08
2019
pubmed:
8
11
2019
medline:
7
8
2021
entrez:
8
11
2019
Statut:
ppublish
Résumé
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is a key component of the hepatitis B burden worldwide. Despite its efficacy to prevent HBV transmission, infant vaccination is not enough to control HBV MTCT. Additional efforts are urgently needed to evaluate and scale-up preventive strategies especially in endemic countries, which are most affected. This review highlights the efficacy and barriers of the currently validated measures for the prevention of HBV MTCT and proposes alternatives adapted to resource-limited settings to eventually achieve HBV elimination worldwide.
Substances chimiques
Hepatitis B Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-349Subventions
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L002086/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R011117/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
World Health Organization. Global hepatitis report; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1. Accessed August 1, 2019
World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2012. Towards Ending Viral Hepatitis. June 2016.
Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399-1408.
World Health Organization. Western Pacific Region. Regional Framework for The Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacifc, 2018-2030. World Health Organization 2018. https://iris.wpro.who.int/bitstream/handle/10665.1/14193/9789290618553-eng.pdf. Accessed August 1, 2019
Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ. 2002;325:569.
Coursaget P, Leboulleux D, Soumare M, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol. 1994;21(2):250-254.
Edmunds WJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117(2):313-325.
Kao J-H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17(6):643-650.
Lin C-L, Kao J-H. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol. 2011;26:123-130.
Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016;44(10):1005-1017.
Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut. 2016;65(12):2007-2016.
Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253(1337):197-201.
Shimakawa Y, Lemoine M, Bottomley C, et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int. 2015;35(10):2318-2326.
Shimakawa Y, Yan HJ, Tsuchiya N, Bottomley C, Hall AJ. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic review. PLoS ONE. 2013;8(7):e69430.
Chiu Y-C, Liao S-F, Wu J-F, et al. Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up. J Pediatr. 2014;165(4):767-72.e1.
Shimakawa Y, Bottomley C, Njie R, Mendy M. The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. BMC Public Health. 2014;14(1):532.
Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006;27(10):2070-2082.
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324-2334.
Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017;45(12):1493-1505.
Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.
Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infec Dis. 2017;23(5):765-772.
Beasley RP, Trepo C, Stevens C, Szmuness W. The eAntigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105(2):94-98.
Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294(14):746-749.
Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol. 1979;3(3):237-241.
Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev25. 2006;19(2):CD004790.
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396-404.
Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31(1):252-259.
Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public health. 2005;36(3):693-699.
Chen Y-S, Zheng H, Liu Y-M, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. Hum Vaccin Immunother. 2016;12(7):1838-1846.
Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31(14):1864-1869.
Ekra D, Herbinger KH, Konate S, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire. Vaccine. 2008;26(22):2753-2761.
Mandal S. Introduction of universal infant hepatitis B immunisation in the UK- paving the way to elimination. Hum Vaccin Immunother. 2019;15(2):440-443.
Hepatitis B. vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92(27):369-392.
Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8):734-746.
Cui F, Li L, Hadler SC, et al. Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992-2005. Vaccine. 2010;28(37):5973-5978.
Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009;200(1):39-47.
Mao B, Patel MK, Hennessey K, Duncan RJ, Wannemuehler K, Soeung SC. Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia. Vaccine. 2013;31(40):4459-4464.
Hutin YJ, Bulterys M, Hirnschall GO. How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc. 2018;21(Suppl 2):e25050.
Miyahara R, Jasseh M, Gomez P, et al. Barriers to timely administration of birth dose vaccines in The Gambia, West Africa. Vaccine. 2016;34(29):3335-3341.
Moturi E, Tevi-Benissan C, Hagan JE, et al. Implementing a birth dose of hepatitis B vaccine in Africa: findings from assessments in 5 countries. J Immunol Sci. 2018;2(5):31-40.
Barbosa C, Smith EA, Hoerger TJ, et al. Cost-effectiveness analysis of the national perinatal hepatitis B prevention program. Pediatrics. 2014;133(2):243-253.
Chen YS, Zheng H, Liu YM, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. Hum Vaccin Immunother. 2016;12(7):1838-1846.
Guo Y, Zhang W, Zhang Y, et al. Cost-effectiveness analysis of preventing mother-to-child transmission of hepatitis B by injecting hepatitis B immune globulin. Eur J Gastro Hepatol. 2012;24(12):1363-1369.
Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773-781.e2.
Brown RS, McMahon BJ, Lok ASF, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63(1):319-333.
Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502-507.
Liu J, Wang J, Yan T, et al. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice. J Viral Hepat. 2019;26:1170-1177.
Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324-2334.
Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-283.
WHO. Practices to improve coverage of the hepatitis B birth dose vaccine; 2012.
Allison RD, Patel MK, Tohme RA. Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth. Vaccine. 2017;35(33):4094-4098.
Sutanto A, Suarnawa IM, Nelson CM, Stewart T, Soewarso TI. Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull World Health Organ. 1999;77(2):119-126.
Diop A, Daff B, Sow M, et al. Oxytocin via Uniject (a prefilled single-use injection) versus oral misoprostol for prevention of postpartum haemorrhage at the community level: a cluster-randomised controlled trial. Lancet Glob Health. 2016;4(1):e37-e44.
Guillermet E, Dicko HM, Mai LTP, et al. Acceptability and feasibility of delivering pentavalent vaccines in a compact, prefilled, autodisable device in Vietnam and Senegal. PLoS ONE. 2015;10(7):e0132292.
Perez Cuevas MB, Kodani M, Choi Y, et al. Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques. Bioeng Transl Med. 2018;3(3):186-196.
WHO. A systematic review of monovalent hepatitis B vaccine thermostability World Health Organization, Geneva; 2017.
Petit D, Tevi-Benissan C, Woodring J, Hennessey K, Kahn A-L. Countries’ interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions. Vaccine. 2017;35(49, Part B):6866-6871.
Scott N, Palmer A, Morgan C, et al. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. Lancet Glob Health. 2018;6(6):e659-e667.
The GAVI.Vaccine Alliance, Vaccine investment strategy. Investment Case: hepatitis B birth dose. https://www.gavi.org/about/strategy/vaccine-investment-strategy/. Accessed August 1, 2019
Patel MK, Capeding RZ, Ducusin JU, de Quiroz CM, Garcia LC, Hennessey K. Findings from a hepatitis B birth dose assessment in health facilities in the Philippines: opportunities to engage the private sector. Vaccine. 2014;32(39):5140-5144.
WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization Copyright (c) World Health Organization 2017; 2017.
Njai HF, Shimakawa Y, Sanneh B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol. 2015;53(4):1156-1163.
Ségéral O, N'Diaye DS, Prak S, et al. Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study. J Clin Virol. 2018;109:29-34.
Seck A, Ndiaye F, Maylin S, et al. Poor sensitivity of commercial rapid diagnostic tests for hepatitis B e Antigen in Senegal, West Africa. Am J Trop Med Hyg. 2018;99(2):428-434.
Siederdissen Honer Zu C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: are we able to change practice? J Viral Hepat. 2018;25(11):1226-1235.
Shimakawa Y, Ndow G, Njie R, et al. Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa. Clin Infect Dis. 2019. [Epub ahead of print] https://doi.org/10.1093/cid/ciz412
Spearman CW, Afihene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2(12):900-909.
Shimakawa Y, Seck A, Nayagam S, Toure-Kane C, Lemoine M. Screening strategies to prevent mother-to-child transmission of hepatitis B in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2018;3(4):222-223.
Mokaya J, Burn EAO, Tamandjou CR, et al. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health. 2019;19(1):829.
WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization Copyright (c) World Health Organization 2015; 2015.
Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-184.
Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911-923.
Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375-386.
Rifat A. Atun SBaAD. When do vertical (stand-alone) programmes have a place in health systems? Policy brief written for the WHO European Ministerial Conference on Health Systems, 25-27 June 2008, Tallinn, Estonia.